FADS1 and hepatocellular carcinoma: We should consider that in all NASH patients, activation of this canonical pathway is a common feature, and some of patients can have additional traits (e.g., FADS1 polymorphisms/decrease enzyme activity) that increase their risk for a faster progression of the disease from NAFL to NASH and/or from NASH to HCC.